Proposed Tax Incentives for Life Sciences Research

Posted on October 11, 2010 by Sheppard Mullin

By Matthew Richardson

A bill was recently introduced in the House of Representatives that would provide significant tax incentives for life sciences research.

Under current law, a 20% tax credit is available for spending on qualified research in excess of a specified base amount, subject to a number of limitations and special rules. Under H.R. 6165, which was introduced last week, this research tax credit would be doubled (to 40%) in the case of "qualified life sciences research."  The bill also doubles the elective "alternative simplified credit" for qualified life sciences research (an alternative method of calculating the research tax credit).
 

Continue Reading...
Tags:
  • Print
  • Comments
  • Share Link

FDA Announces Much Anticipated Public Hearing on Biosimilars

Posted on October 7, 2010 by Sheppard Mullin

By Deborah M. Shelton

Having had the opportunity to analyze the biosimilars provisions of the new health care law enacted this past March, stakeholders have at long last the chance on November 2-3 to weigh in on FDA's implementation of the biosimilar approval pathway. FDA will hold a two-day public hearing on November 2-3, 2010, from 8:30 am to 4:30 pm, at the FDA Conference Center on FDA's campus in White Oak, Maryland.  FDA published its official announcement of the public hearing in the October 5th issue of the Federal Register. 75 Fed. Reg. 61497 (Oct. 5, 2010). Here is the link to the Federal Register Notice: http://edocket.access.gpo.gov/2010/pdf/2010-24853.pdf.
 

Continue Reading...
Tags:
  • Print
  • Comments
  • Share Link